Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318370 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT00318370: Completed Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Morphotek.
NCT00318370 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Morphotek. The registered enrollment target is 58 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318370, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer. MORAb-003 is a monoclonal antibody directed against an antigen on most ovarian cancers.
Primary Outcome
Defined using modified Gynecologic Cancer Intergroup (GCIG) criteria: Number of participants who achieved a 50% response = \>50% decrease from baseline CA-125 (higher of 2 pretreatment CA-125 assessments and the level must be at least 52.5 kU/L).
Conditions Studied
Interventions
- DRUG Farletuzumab
- DRUG Chemo Plus Far
Study Locations (20)
Louisiana
- Hematology and Oncology Specialists, LLC - Covington
- Jayne Gurtler, M.D. - Metairie
- Hematology and Oncology Specialists, LLC - Metarie
New Jersey
- The Center for Cancer and Hematologic Disease - Cherry Hill
- The Cancer Institute of New Jersey - New Brunswick
- Cooper University Hospital - Voorhees Township
Texas
- Mary Crowley Medical Research Center - Dallas
- South Texas Oncology & Hematology - San Antonio
- Tyler Cancer Center - Tyler
Virginia
- Northern Virginia Pelvic Surgery Associates - Annandale
- Peninsula Cancer Center - Newport News
Other
- Krankenhaus Nordwest - Frankfurt
- Nationales Centrum fur Tumorerkrankungen - Heidelberg
California
- Sharp HealthCare - San Diego
Indiana
- St. Vincent Gynecologic Oncology - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00318370 record still lists
NCT00318370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Farletuzumab is the first listed.
NCT00318370 names 20 study sites across 12 states, led by Louisiana, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT00318370 about?
NCT00318370 is a clinical study titled "Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy". The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer. MORAb-003 is a monoclonal antibody directed against an antigen on most ovarian cancers.
What is the current status of trial NCT00318370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2006-05. Estimated completion is 2010-06.
What conditions does trial NCT00318370 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT00318370?
The interventions under investigation include: Farletuzumab (DRUG), Chemo Plus Far (DRUG).
Who is sponsoring clinical trial NCT00318370?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00318370 being conducted?
This trial has 20 study locations across California, Indiana, Louisiana, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00318370's enrollment target sits among peer trials
58 201st of 322 higher than 121 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia